Cytomed TherapeuticsGDTC
13F holders, Q1 2025 (March 31)2holders +1
1new positions
0sold out
1famous investor
$2.22avg. 13F price*
At the end of Q1 2025, 2 institutions reported holding Cytomed Therapeutics Ltd. (GDTC) in their 13F filings, up 1 from Q4 2024. 1 opened new positions and 0 sold out. The largest holders were Citadel Advisors ($39K) and UBS Group AG ($31K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Cytomed Therapeutics Ltd.
- CUSIP
- Y1R80M106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $39K |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 21,599 shares bought, net +21,599 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Citadel Advisors | 0.00% | New | 17,250 | $39K |
| UBS Group AG | 0.00% | Add +43.1% | 14,447 | $31K |
"% of holder's portfolio" is GDTC's weight in each manager's 13F, not the share of Cytomed Therapeutics Ltd. the manager owns.